Roche has agreed to acquire Telavant Holdings — the maker of an inflammatory bowel disease drug — from Roivant Sciences and Pfizer for $7.25 billion, the Switzerland-based company said in an Oct. 23 news release.
Read the full post on Becker's Hospital Review - Healthcare News
